📊 CBIH Key Takeaways
Is Cannabis Bioscience International Holdings, Inc. (CBIH) a Good Investment?
Cannabis Bioscience International is a fundamentally distressed company with severe financial deterioration across all key metrics. The company exhibits negative stockholders' equity of $1.4M, massive operating losses, critically low liquidity (0.02x current ratio), and minimal revenue generation ($77.5K) insufficient to cover any operating expenses. The combination of insolvency, negative cash flows, and inability to generate profits makes this an extremely high-risk investment unsuitable for most portfolios.
CBIH shows a weak fundamental profile: revenue is very small, operating losses vastly exceed gross profit, and net margins remain deeply negative despite modest year-over-year improvement. Financial health is severely strained by negative equity, near-zero cash, and extremely poor liquidity, while free cash flow is heavily negative relative to the scale of the business.
Why Buy Cannabis Bioscience International Holdings, Inc. Stock? CBIH Key Strengths
- High gross margin of 75.9% indicates strong product-level economics if revenue could scale
- Year-over-year revenue growth of 21.8% shows some demand for services
- Relatively low total debt of $291.2K in absolute terms
- Revenue grew 21.8% year over year from a small base
- Gross margin is relatively strong at 75.9%
- Net loss and diluted EPS improved modestly year over year
CBIH Stock Risks: Cannabis Bioscience International Holdings, Inc. Investment Risks
- Negative stockholders' equity of -$1.4M indicates technical insolvency and potential total loss of equity value
- Critical liquidity crisis with current ratio of 0.02x and only $132 in cash against $1.4M in liabilities
- Massive operating losses (-$170.7K) and negative free cash flow (-$4.7M) with negligible revenue ($77.5K) unable to sustain operations
- Severely negative operating margin (-220.3%) and net margin (-257.7%) indicating structural unprofitability
- Capital expenditure of $4.6M against only $77.5K in revenue demonstrates unsustainable spending patterns
- No insider activity in last 90 days suggesting potential loss of management confidence
- Negative operating and net margins indicate the business model is not covering overhead
- Balance sheet is distressed with negative stockholders' equity and only $132 of cash
- Liquidity and cash flow are extremely weak, with a 0.02x current ratio and deeply negative free cash flow
Key Metrics to Watch
- Cash balance trend and runway to insolvency
- Revenue growth sustainability and operating expense reduction initiatives
- Debt refinancing or capital restructuring announcements to address negative equity
- Operating cash flow and free cash flow trend
- Revenue scale-up relative to operating expenses and liquidity improvement
Cannabis Bioscience International Holdings, Inc. (CBIH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CBIH Profit Margin, ROE & Profitability Analysis
CBIH vs Healthcare Sector: How Cannabis Bioscience International Holdings, Inc. Compares
How Cannabis Bioscience International Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cannabis Bioscience International Holdings, Inc. Stock Overvalued? CBIH Valuation Analysis 2026
Based on fundamental analysis, Cannabis Bioscience International Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cannabis Bioscience International Holdings, Inc. Balance Sheet: CBIH Debt, Cash & Liquidity
CBIH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cannabis Bioscience International Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 4% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
CBIH Revenue Growth, EPS Growth & YoY Performance
CBIH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $53.3K | -$76.3K | $0.00 |
| Q1 2026 | $24.2K | -$76.3K | $0.00 |
| Q1 2025 | $72.8K | -$76.3K | $0.00 |
| Q3 2024 | $36.4K | -$124.4K | $0.00 |
| Q2 2024 | $63.7K | -$124.4K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cannabis Bioscience International Holdings, Inc. Dividends, Buybacks & Capital Allocation
CBIH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cannabis Bioscience International Holdings, Inc. (CIK: 0001411057)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CBIH
What is the AI rating for CBIH?
Cannabis Bioscience International Holdings, Inc. (CBIH) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CBIH's key strengths?
Claude: High gross margin of 75.9% indicates strong product-level economics if revenue could scale. Year-over-year revenue growth of 21.8% shows some demand for services. ChatGPT: Revenue grew 21.8% year over year from a small base. Gross margin is relatively strong at 75.9%.
What are the risks of investing in CBIH?
Claude: Negative stockholders' equity of -$1.4M indicates technical insolvency and potential total loss of equity value. Critical liquidity crisis with current ratio of 0.02x and only $132 in cash against $1.4M in liabilities. ChatGPT: Negative operating and net margins indicate the business model is not covering overhead. Balance sheet is distressed with negative stockholders' equity and only $132 of cash.
What is CBIH's revenue and growth?
Cannabis Bioscience International Holdings, Inc. reported revenue of $77.5K.
Does CBIH pay dividends?
Cannabis Bioscience International Holdings, Inc. does not currently pay dividends.
Where can I find CBIH SEC filings?
Official SEC filings for Cannabis Bioscience International Holdings, Inc. (CIK: 0001411057) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CBIH's EPS?
Cannabis Bioscience International Holdings, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CBIH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cannabis Bioscience International Holdings, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CBIH stock overvalued or undervalued?
Valuation metrics for CBIH: ROE of N/A (sector avg: 15%), net margin of -257.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CBIH stock in 2026?
Our dual AI analysis gives Cannabis Bioscience International Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CBIH's free cash flow?
Cannabis Bioscience International Holdings, Inc.'s operating cash flow is $-109.2K, with capital expenditures of $4.6M. FCF margin is -6,093.5%.
How does CBIH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -257.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.02 (avg: 2).